This dual strategy downregulates anti-apoptotic proteins MCL-1 and BCL-XL, which are increased in TP53 mutant AML, while simultaneously upregulating BAK, BAX, PUMA, and NOXA to decisively promote apoptosis [175]. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.